Thermo Fisher Scientific UT, Urotensin Receptor Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A synthetic peptide presents part of carboxyl - terminal tail of human UT. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Urotensin II Receptor,uniProtId:Q9UKP6-1,ncbiNodeId:9606,antigenRange:389,antigenLength:389,antigenImageFileName:7TM0365N_Urotensin_II_Receptor_Q9UKP6-1_Rabbit.svg,antigenImageFileNamePDP:7TM0365N_Urotensin_II_Receptor_Q9UKP6-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

Dulbecco`s PBS, pH 7.4

Contains

0.02% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice (domestic); Dry ice (international)

Target Information

The Urotensin-II receptor has been reported to be expressed at high levels in the heart and pancreas and also in artery and smooth muscle. Low transcript levels have been identified in brain, particularly in thalamus, and superior occipital gyrus. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This turn-off activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.